***Pharmaceutical Benefits Advisory Committee***

Telephone: (02) 6289 7099 Address all mail to:

Email: PBAC@health.gov.au PBAC Secretariat

GPO Box 9848

Canberra ACT 2601

**DELETION OF PHARMACEUTICAL BENEFIT ITEMS**

**EFFECTIVE 1 January 2020**

Following is the advice of the Pharmaceutical Benefits Advisory Committee concerning the deletion of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act* *1953*, with effect from the above date.

|  |  |
| --- | --- |
| **Item** | **PBAC Advice** |
| Verteporfin | The sponsor has requested the deletion of Visudyne® from the PBS. The sponsor stated that the product will be transferred to them (from Novartis Pharmaceuticals), effective 1 November 2019. After this date, registered supply of the product will cease, as the small volumes of supply are not commercially viable. The product will remain available to the small patient population via unlicensed supply.  The PBAC noted that aflibercept and ranibizumab are PBS-listed for the same indication (subfoveal choroidal neovascularisation (CNV) due to macular degeneration) and there were very few services of verteporfin in 2018-19. The PBAC had no objections to this deletion request. |

John Paul

Director

Health Technology Assessment Section

Office of Health Technology Assessment

Technology Assessment and Access Division

29 November 2019